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Bone resorption inhibitors
The osteoclast vacuolar-ATPase plays an essential role in bone resorption, and inhibition of
this acid pump has been shown to inhibit bone resorption both in vitro and in vivo. Inhibitors
of bone resorption are potentially useful for the treatment of osteoporosis, i.e., the loss of
bone (Solid phase synthesis of diamides as potential bone resorption inhibitors, K. M.
Edvinsson et. al., Bioorg. & Med. Chem. Lett., 10, (2000), 503-507). A library of 806
individual compounds was synthesised on Rink chloride solid support. One of the most potent
compounds obtained, when screened at 9µM for effect on vacuolar-ATPase mediated proton
transport in membrane vesicles derived from chicken medullary bone, was (i) which gave 51%
inhibition. However, no clear structure activity relationships (SAR) could be deduced from the
compounds contained within this library, and further work will be necessary to establish the
credentials of this class of diamides as potential bone resorption inhibitors.
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Antibiotics effective against Vancomycin-resistant bacteria
Vancomycin, a prominent member of the glycopeptide class of antibiotics, has been used
clinically for the past 40 years to treat infections caused by gram-positive bacteria. Its
renowned action against methicillin-resistant Staphylococcus aurens (MRSA) bacteria has
made it an antibiotic of last resort. However, the emergence of vancomycin-resistant
enterococci (VRE) and, more recently, vancomycin intermediate susceptible Staphylococcus
aurens (VISA) are raising serious health concerns and has prompted renewed and vigorous
research activities targeting modified vancomycin analogues with restored activity against
VRE or VISA (Target-accelerated combinatorial synthesis and discovery of highly potent
antibiotics effective against vancomycin-resistant bacteria, K. C. Nicolaou et. al., Angew.
Chem. Int. Ed., 39, (2000), 3823-3828). Vancomycin's antibacterial activity arises from its
ability to inhibit peptidoglycan biosynthesis within the bacterial cell wall. Specifically,
vancomycin binds to the terminal Lys-D-Ala-D-Ala fragment of the growing peptidoglycan
biosynthetic precursor through an intricate network of five hydrogen bonds, thereby inhibiting
cell-wall growth and cross-linking. A library of 30 compounds was synthesised in solution
using 'dynamic target-accelerated combinatorial synthesis' (TACS) of vancomycin dimers for
the identification of ligands with the highest affinity for vancomycin's receptor D-Ala-D-Ala.
TACS is a process whereby building blocks of a combinatorial library are allowed to assemble
and react in the presence of a target. This synthetic approach should selectively deliver the
product with the highest affinity for the target out of a virtual library of all possible reaction
products. In this way, several compounds from this library were produced which possess
potent activities against VRE and VISA that rival or exceed the most active compounds
known today for these bacterial strains. The TACS concept has been shown to be a powerful
technique for the generation of highly potent antibiotics active against VRE and VISA, and the
acute need for new antibiotics dictates further development of these compounds.
